Literature DB >> 1606994

Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance.

A Hedman1, B Angelin, A Arvidsson, R Dahlqvist.   

Abstract

The possibility of an inhibitory effect of spironolactone on the biliary clearance of digoxin has been investigated in 6 healthy subjects. Plasma clearance and the renal and biliary clearance of digoxin were determined twice at steady state (digoxin 0.5 to 1 mg.d-1 p.o. for 6 days), alone or in combination with spironolactone 200 mg daily, after an intravenous dose of digoxin (0.7 x oral dose) on Day 7. Plasma and urine were collected for 48 h. Biliary clearance of digoxin was determined on Day 8 by a duodenal perfusion technique. During spironolactone treatment plasma digoxin clearance tended to be lower (255 vs 224 ml/min; P = 0.057) and renal clearance significantly lower (166 vs 144 ml/min), while the biliary clearance of digoxin remained unchanged (106 vs 103 ml/min). Thus, spironolactone reduced the renal clearance of digoxin by an average of 13%, without affecting its biliary clearance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606994     DOI: 10.1007/bf00314854

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  Renal tubular secretion of digoxin.

Authors:  E Steiness
Journal:  Circulation       Date:  1974-07       Impact factor: 29.690

2.  Biliary secretion of ouabain-3H and its uptake by liver slices in the rat.

Authors:  H J Kupferberg; L S Schankl
Journal:  Am J Physiol       Date:  1968-05

3.  On the problem of a common hepatic transport process for steroids. Uptake of 3-H-taurocholic acid and 3-H-corticosterone into rat liver slices.

Authors:  R R Erttmann; K H Damm
Journal:  Arch Int Pharmacodyn Ther       Date:  1975-04

4.  [The pharmacokinetics of digoxin during chronic spironolacton treatment (author's transl)].

Authors:  J P Masson; O Bass; H R Baur; E E Ohnhaus
Journal:  Klin Wochenschr       Date:  1978-11-01

5.  Quinidine reduces biliary clearance of digoxin in man.

Authors:  B Angelin; A Arvidsson; R Dahlqvist; A Hedman; K Schenck-Gustafsson
Journal:  Eur J Clin Invest       Date:  1987-06       Impact factor: 4.686

6.  New insights into the pharmacokinetics of spironolactone.

Authors:  H W Overdiek; W A Hermens; F W Merkus
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

7.  Spironolactone as a source of interference in commercial digoxin immunoassays.

Authors:  R G Morris; P Y Lagnado; D R Lehmann; D B Frewin; M L Glistak; R B Burnet
Journal:  Ther Drug Monit       Date:  1987-06       Impact factor: 3.681

8.  No effect of probenecid on the renal and biliary clearances of digoxin in man.

Authors:  A Hedman; B Angelin; A Arvidsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

9.  Spironolactone-induced changes in digoxin kinetics.

Authors:  S Waldorff; J D Andersen; N Heebøll-Nielsen; O G Nielsen; E Moltke; U Sørensen; E Steiness
Journal:  Clin Pharmacol Ther       Date:  1978-08       Impact factor: 6.875

10.  Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis.

Authors:  K Nilsell; B Angelin; B Leijd; K Einarsson
Journal:  Gastroenterology       Date:  1983-12       Impact factor: 22.682

View more
  7 in total

1.  Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Authors:  Donna A Volpe; Salaheldin S Hamed; Lei K Zhang
Journal:  AAPS J       Date:  2013-12-13       Impact factor: 4.009

Review 2.  Differential pharmacokinetics of digoxin in elderly patients.

Authors:  C G Hanratty; P McGlinchey; G D Johnston; A P Passmore
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 3.  Methods to evaluate biliary excretion of drugs in humans: an updated review.

Authors:  Giulia Ghibellini; Elaine M Leslie; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

4.  Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.

Authors:  E Yukawa; F Suematu; M Yukawa; M Minemoto; S Ohdo; S Higuchi; Y Goto; T Aoyama
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.

Authors:  Mariam Abdel Jalil; Noura Abdullah; Mervat Alsous; Khawla Abu-Hammour
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-05       Impact factor: 2.441

6.  Inhibition by basic drugs of digoxin secretion into human bile.

Authors:  A Hedman
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 7.  Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.

Authors:  Giulio Di Mizio; Gianmarco Marcianò; Caterina Palleria; Lucia Muraca; Vincenzo Rania; Roberta Roberti; Giuseppe Spaziano; Amalia Piscopo; Valeria Ciconte; Nunzio Di Nunno; Massimiliano Esposito; Pasquale Viola; Davide Pisani; Giovambattista De Sarro; Milena Raffi; Alessandro Piras; Giuseppe Chiarella; Luca Gallelli
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.